D.E. Shaw & Co
OCUL icon

D.E. Shaw & Co’s Ocular Therapeutix OCUL Stock Holding History

D.E. Shaw & Co’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Sell
218,478
-935,432
-81% -$8.92M ﹤0.01% 2975
2025
Q4 		$14M Buy
1,153,910
+1,040,631
+919% +$12.6M 0.01% 1474
2025
Q3 		$1.32M Buy
113,279
+10,446
+10% +$125K ﹤0.01% 3274
2025
Q2 		$954K Buy
102,833
+42,710
+71% +$334K ﹤0.01% 3260
2025
Q1 		$441K Buy
60,123
+28,704
+91% +$221K ﹤0.01% 3568
2024
Q4 		$268K Buy
+31,419
New +$307K ﹤0.01% 3948
2024
Q2 		– Sell
-160,142
Closed -$1.46M – 4747
2024
Q1 		$1.46M Sell
160,142
-230,693
-59% -$1.64M ﹤0.01% 2850
2023
Q4 		$1.74M Sell
390,835
-194,045
-33% -$574K ﹤0.01% 2775
2023
Q3 		$1.84M Sell
584,880
-71,225
-11% -$291K ﹤0.01% 2647
2023
Q2 		$3.39M Sell
656,105
-443,665
-40% -$2.64M ﹤0.01% 2185
2023
Q1 		$5.8M Buy
1,099,770
+131,436
+14% +$624K 0.01% 1813
2022
Q4 		$2.72M Buy
968,334
+176,045
+22% +$583K ﹤0.01% 2669
2022
Q3 		$3.29M Buy
792,289
+43,824
+6% +$221K ﹤0.01% 2535
2022
Q2 		$3.01M Buy
748,465
+134,927
+22% +$510K ﹤0.01% 2706
2022
Q1 		$3.04M Buy
613,538
+133,870
+28% +$742K ﹤0.01% 2871
2021
Q4 		$3.34M Sell
479,668
-87,434
-15% -$679K ﹤0.01% 2827
2021
Q3 		$5.67M Sell
567,102
-120,078
-17% -$1.35M 0.01% 1989
2021
Q2 		$9.74M Buy
687,180
+35,052
+5% +$533K 0.01% 1521
2021
Q1 		$10.7M Sell
652,128
-397,618
-38% -$7.66M 0.01% 1307
2020
Q4 		$21.7M Buy
1,049,746
+776,758
+285% +$11.5M 0.02% 917
2020
Q3 		$2.08M Sell
272,988
-148,546
-35% -$1.23M ﹤0.01% 2376
2020
Q2 		$3.51M Buy
421,534
+381,362
+949% +$2.53M ﹤0.01% 1939
2020
Q1 		$199K Buy
+40,172
New +$198K ﹤0.01% 3649
2018
Q4 		– Sell
-211,609
Closed -$1.46M – 3922
2018
Q3 		$1.46M Buy
211,609
+37,586
+22% +$236K ﹤0.01% 2423
2018
Q2 		$1.18M Buy
+174,023
New +$1.2M ﹤0.01% 2605
2018
Q1 		– Sell
-60,057
Closed -$267K – 3705
2017
Q4 		$267K Buy
60,057
+2,911
+5% +$14.9K ﹤0.01% 3288
2017
Q3 		$353K Buy
57,146
+14,768
+35% +$95.1K ﹤0.01% 3079
2017
Q2 		$393K Sell
42,378
-94,375
-69% -$913K ﹤0.01% 2916
2017
Q1 		$1.27M Buy
136,753
+118,800
+662% +$989K ﹤0.01% 2152
2016
Q4 		$150K Buy
17,953
+2,806
+19% +$21.8K ﹤0.01% 3313
2016
Q3 		$104K Sell
15,147
-41,740
-73% -$254K ﹤0.01% 3284
2016
Q2 		$282K Sell
56,887
-32,843
-37% -$325K ﹤0.01% 3045
2016
Q1 		$867K Buy
+89,730
New +$680K ﹤0.01% 2448
2015
Q4 		– Sell
-11,567
Closed -$163K – 3934
2015
Q3 		$163K Sell
11,567
-70,061
-86% -$1.41M ﹤0.01% 3548
2015
Q2 		$1.72M Buy
+81,628
New +$2.02M ﹤0.01% 2306
2014
Q4 		– Sell
-13,684
Closed -$205K – 4180
2014
Q3 		$205K Buy
+13,684
New +$202K ﹤0.01% 3880

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co's OCUL Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Ocular Therapeutix (OCUL) stake by 81% in Q1 2026, selling an estimated $8.92M and leaving 218,478 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2975.

D.E. Shaw & Co first reported a position in OCUL in Q3 2014 and has held it in 36 quarters since. The position peaked at $21.7M in Q4 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • D.E. Shaw & Co held 218,478 shares of Ocular Therapeutix worth $1.85M as of Q1 2026.
  • D.E. Shaw & Co sold 935,432 Ocular Therapeutix shares in Q1 2026, an estimated $8.92M.
  • Ocular Therapeutix made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2975 holding.
  • D.E. Shaw & Co first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 36 quarters since.
  • D.E. Shaw & Co's Ocular Therapeutix position peaked at $21.7M in Q4 2020.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.